On Thursday, January 16, 2025, Cathie Wood‘s Ark Invest made significant trades, prominently increasing its stake in CRISPR Therapeutics AG while also adding to its position in Ibotta Inc.
The CRISPR Therapeutics Trade On Thursday, Ark Invest bolstered its holdings in CRISPR Therapeutics AG (NASDAQ: CRSP) by purchasing 132,594 shares across its ARKG and ARKK ETFs.
The stock closed at $40.30, making the total investment approximately $5.34 million. This move follows Ark’s previous interest in the biotech sector, as evidenced by recent acquisitions in Illumina Inc.
The Ibotta Trade Ark Invest also made a noteworthy purchase of 10,742 shares of Ibotta Inc (NYSE: IBTA) through its ARKF ETF.
The shares closed at $73.25, valuing the transaction at approximately $787,000.
Ibotta, known for its cash-back rewards program, fits well into Ark’s vision of a digital-first financial ecosystem.
Other Key Trades:
- Sold 103,064 shares of Accolade Inc (NASDAQ: ACCD) from the ARKG ETF, valued at about $707,000 based on the closing price of $6.86.